HL
Therapeutic Areas
SIGA Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TPOXX (tecovirimat) Oral | Human Smallpox Disease | Approved |
| TPOXX (tecovirimat) IV | Human Smallpox Disease | Approved |
| TPOXX (tecovirimat) | Complications from Vaccinia Vaccination | Phase 3 |
| Next-Generation Orthopoxvirus Inhibitors | Orthopoxvirus Infections | Pre-clinical |
Leadership Team at SIGA Technologies
DJ
Daniel J. Luckshire
Chief Executive Officer and Chairman of the Board
DE
Dennis E. Hruby
Chief Scientific Officer
D(
Dieter (DJ) J. Weinand
Lead Independent Director
JJ
James J. Antal
Director
JM
Julie M. Kane
Director
GJ
Gary J. Nabel
Director
JL
Jaymie L. Durnan
Senior Vice President, Product Development & Manufacturing
MT
Michael T. Klemba
Vice President, Discovery Research
TH
Todd H. Davies
Vice President, Business Development & Government Affairs